LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

Sector Healthcare

16.09 -0.62

Buy Sell

Overview

Share price change

24h

Current

Min

15.97

Max

16.09

Key metrics
By Trading Economics
Income	17M 33M
Sales	36M 242M
EPS	0.2
Profit margin	13.797
Employees	597
EBITDA	12M 33M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+67.58 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	119M 2.7B
Previous open	16.71
Previous close	16.09

News Sentiment

By Acuity

100%

340 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

15.69 / 16.33 Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Related News

6 Sept 2024, 22:41 UTC

Market Talk

KinderCare and StandardAero File for IPOs -- Market Talk

6 Sept 2024, 21:18 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 Sept 2024, 21:05 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 Sept 2024, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 Sept 2024, 20:39 UTC

Earnings

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 Sept 2024, 20:35 UTC

Top News

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 Sept 2024, 20:34 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 Sept 2024, 20:11 UTC

Top News

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 Sept 2024, 19:51 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 Sept 2024, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 Sept 2024, 19:14 UTC

Market Talk

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 Sept 2024, 19:01 UTC

Market Talk

Gold Slips on Prevailing Uncertainty -- Market Talk

6 Sept 2024, 18:27 UTC

Top News

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 Sept 2024, 18:25 UTC

Market Talk

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 Sept 2024, 18:15 UTC

Top News

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 Sept 2024, 18:12 UTC

Top News

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 Sept 2024, 17:44 UTC

Market Talk

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 Sept 2024, 17:30 UTC

Market Talk

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 Sept 2024, 17:30 UTC

Top News

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 Sept 2024, 17:27 UTC

Top News

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 Sept 2024, 17:00 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6 Sept 2024, 17:00 UTC

Market Talk

Mexican Inflation Seen Easing in August -- Market Talk

6 Sept 2024, 16:36 UTC

Market Talk

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 Sept 2024, 16:35 UTC

Earnings

Hot Stocks

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 Sept 2024, 16:33 UTC

Acquisitions, Mergers, Takeovers

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 Sept 2024, 16:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Earnings

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 Sept 2024, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 Sept 2024, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

67.58% upside

12 Months Forecast

Average 26.93 USD 67.58%

High 39 USD

Low 17 USD

Based on 18 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

18 ratings

Buy

Hold

Sell

Based on 18 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

15.69 / 16.33Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

340 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).